Fremont, CA (Vocus/PRWEB) March 16, 2011
Optovue, a pioneer in spectral-domain optical coherence tomography (OCT), announced the launch of a new wellness program implemented as a “pay per visit” arrangement with eye care clinicians, The iHealthcheck Program was revealed to great acclaim at the “Heart of America Contact Lens Society” meeting in Kansas City MO.
The iHealthcheck exam has been added to the portable new spectral OCT from Optovue - the iVue – which was launched in 2010 and already setting industry records. The incorporation of the new iHealthcheck exam which scans for both retinal and glaucomatous pathology will complement the everyday comprehensive eye exam. This pay per use model will allow an office to provide better medical care and a wellness testing option with no capital outlay. The diagnostic capabilities of the practice will be greatly advanced with the implementation of the program.
The iHealthcheck is non-invasive and performed quickly and easily as an initial step in a comprehensive eye exam. The images produced provide a cross sectional view of the retinal layers with resolution to 5 microns. In addition to the cross sectional views, the iHealthcheck provides a retinal thickness map and a ganglion cell complex map. These outputs enable the doctor to identify very early signs of disease, or confirm ocular health.
Early detection of retinal abnormalities and disease may lead to earlier and safer treatments and in many cases prevent or slow vision loss. The iHealthCheck is recommended annually regardless of symptoms, thereby allowing eye doctors to observe any subtle changes occurring over time.
About RTVue® and iVue™
RTVue was the first FDA cleared Fourier domain (also known as spectral domain) OCT launched in the United States, and also the first OCT cleared by the U.S. Food and Drug Administration for both corneal and retinal imaging. The iVue is the compact fourier-domain version of the RTVue OCT, offering the same scanning speed and resolution as the larger system, that includes scanning and reports for retina, retina nerve fiber and cornea assessment by the clinician.
About Optovue® (http://www.optovue.com)
Optovue Inc. is a privately-held ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease. Optovue has achieved widespread market success through a combination of unique data analysis design, a reputation for excellent customer service, and rapid innovation of its technology in response to physician feedback. The company is headquartered in Fremont, CA, with operations in Carlsbad, CA and European operations in Heidelberg, Germany.
Vice President Regulatory
Vice President Marketing